Harrow Emerging As Dominant Operator In U.S. Ophthalmic Market

Harrow, Inc. is rapidly evolving into a dominant US ophthalmic pharma player, with a 30-fold revenue increase since 2015 and ...

Regeneron Pharmaceuticals, Inc. (REGN) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Tyler Van Buren here, senior biotech analyst at TD Cowen. Thank you very much for joining TD Cowen's 46th Annual Healthcare Conference. For next session or first session of the day, actually, very ...

Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients

Patients treated with olatorepatide achieved up to 19% body-weight loss at week 48 Regeneron’s global Phase 3 registrational program to be ...

Regeneron Pharmaceuticals, Inc.: Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients

Patients treated with olatorepatide achieved up to 19% body-weight loss at week 48 Regeneron's global Phase 3 registrational program to be initiated later this year TARRYTOWN, N.Y., March 09, 2026 (GL ...
Medical Xpress

New imaging technique could transform precision of vocal fold injection procedures

Researchers at Stanford University, in collaboration with scientists at the German Cancer Institute, have shown for the first time that shortwave infrared (SWIR) imaging can be used to visualize ...
PharmiWeb

Bayer receives MHRA authorisation for third retinal indication of Eylea® (aflibercept 8 mg) for treatment of retinal vein occlusion

The MHRA has granted marketing authorisation for Eylea ® (aflibercept 8 mg) for the treatment of patients with macular oedema following retinal vein occlusion (RVO) including branch, central and ...
Healio

Case 2: Long-term Results and Follow-up

In this video, Jay Chhablani, MD, director of clinical research at the UPMC Vision Institute, professor of ophthalmology and vice chair of clinical trials at University of Pittsburgh School of ...

Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)

Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery ...